Lipid nanoparticles for mRNA delivery
By Xucheng Hou, T. Zaks, R. Langer, Yizhou Dong. Nature Reviews Materials, 2021
3,237 citations recorded by the source corpus.
Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent and treat various diseases. To function in vivo, mRNA requires safe, effective and stable delivery systems that protect the nucleic acid from degradation and that allow cellular uptake and mRNA release. Lipid nanoparticles have successfully entered the clinic for the delivery of mRNA; in particular, lipid nanoparticle–mRNA vaccines are now in clinical use against coronavirus disease 2019 (COVID-19), which marks a milestone for mRNA therapeutics. In this Review, we discuss the design of lipid nanoparticles for mRNA delivery and examine physiological barriers and possible administration routes for lipid nanoparticle–mRNA systems. We then consider key points for the clinical translation of lipid nanoparticle–mRNA formulations, including good manufacturing practice, stability, storage and safety, and highlight preclinical and clinical studies of lipid nanoparticle–mRNA therapeutics for infectious diseases, cancer and genetic disorders. Finally, we give an outlook to future possibilities and remaining challenges for this promising technology. Lipid nanoparticle–mRNA formulations have entered the clinic as coronavirus disease 2019 (COVID-19) vaccines, marking an important milestone for mRNA therapeutics. This Review discusses lipid nanoparticle design for mRNA delivery, highlighting key points for clinical translation and preclinical studies of lipid nanoparticle–mRNA therapeutics for various diseases.
Subfields: Animal Science and Zoology, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/7c83d62efc04c88e00e516f01113586884264cd0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- N-N Xie
- Zhao Huang
- Wei Gao
- Li Fu
- Canhua Huang
- G. Shen
Citations in the corpus
- Neoantigens: promising targets for cancer therapy (2023, background): “The lipid nanoparticle-formulated mRNA-4157 and mRNA-4650 vaccines are used alone in individuals with primary solid tumors or in combination with PD-1 inhibitor (NCT03313778, NCT03897881, NCT03480152).(338) Advanced RNA-lipoplex formulations have been developed and explored as therapeutic cancer vac”
- The role of lipid components in lipid nanoparticles for vaccines and gene therapy (2022, neutral): “2022), as well as current literature [14,114].”